BioCentury
ARTICLE | Company News

Tekmira changing name to Arbutus with HBV focus

July 21, 2015 12:46 AM UTC

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) said it will change its name to Arbutus Biopharma Corp., effective Aug. 3, and will focus on developing HBV therapies. It will form a separate business unit for non-HBV therapies, and will suspend development of TKM-Ebola to treat Ebola. The company will trade on NASDAQ under the ticker ABUS.

Tekmira is developing a portfolio of therapies it hopes to test in combinations to cure HBV. The company hopes to begin a Phase IIa study of TKM-HBV this half and a Phase I trial of TKM- PLK1 in 1H16; it intends to begin clinical trials of two more candidates in 1H16. ...